← Eichor
Condition: Nk Cell Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nk Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07283679An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06693973A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010005"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Phase 1/Phase 2 · 1 location(s) · Mingzhi Zhang · NCT06559553The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Aibin Liang，MD，Ph.D. · NCT05842707Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT02974647PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NA · 1 location(s) · Ruijin Hospital · NCT05662540Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06824883A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT04365036Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm
Phase 1/Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT07525466A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/Phase 2 · 37 location(s) · Dren Bio · NCT05475925Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage
Phase 2 · 3 location(s) · Peking University Cancer Hospital & Institute · NCT07000617A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/
Phase 1 · 1 location(s) · Emercell SAS · NCT07044050Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Phase 2 · 1 location(s) · Won Seog Kim · NCT05477264Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Rong Tao · NCT07502768Universal 4SCAR7U Targeting CD7-positive Malignancies
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05995028Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092451Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07444632A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT05978141Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
Phase 1/Phase 2 · 1 location(s) · Bangdong Gong · NCT06967038Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT054725583'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.